Matthew K. Szot, Chief Financial Officer at Cadrenal Therapeutics, Inc. (CVKD), sold 19,866 shares at $6.97 ($138K) on 2025-12-29, disclosed to the SEC on 2025-12-31.
Scheduled sale ($138k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.97 | 9,933 | $69K | 50.0% |
| 2 | $6.97 | 9,933 | $69K | 50.0% |
| Total | $6.97 avg | 19,866 | $138K | 100% |
| Filing → |
| CVKD | SELL | 2025-10-28 | $50K | — | Filing → |
| CVKD | SELL | 2025-10-14 | $49K | — | Filing → |
| CVKD | SELL | 2025-10-07 | $1K | — | Filing → |